King Pharmaceuticals, Lexon and Alissa Healthcare covertly shared sensitive data through messages and a hotel meeting to skew the UK drugs market and maintain high prices of antidepressant drug nortriptyline, the Competition and Markets Authority has said today. < The CMA had already fined the companies a total of 3.4 million pounds<
* = Required Field
*Areas of Interest
MLex content is primarily organized into different areas of interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .
Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.